 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Medical News Glaxo-Vertex Study Tests Anti-HIV DrugsMay 17, 2006 On Tuesday, GlaxoSmithKline PLC (GSK) and Vertex Pharmaceuticals Inc. said early results from a clinical study show their HIV drug Lexiva is comparable to Abbott Laboratories Inc.'s combination drug Kaletra. The study's 887 patients received twice a day either Lexiva (700 mg) along with ritonavir (100 mg), the active ingredient in Abbott's Norvir, or Kaletra (400 mg) with ritonavir (100 mg). Once a day, patients in both groups received abacavir (600 mg) and lamivudine (300 mg), the active ingredients in GSK's HIV drugs Ziagen and Epivir. After 48 weeks, 73 percent of Lexiva patients achieved suppression of HIV replication, compared to 71 percent of the Kaletra patients, according to the study. Associated Press 05.16.06  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
